Sucampo Pharmaceuticals
Bethesda
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 51 – 100
- Estimated revenue: $100K – $500K
- Total funding: $300.0M
- Funding stage: M&A
- Last round: Post-IPO Debt (Dec 2016)
- Ticker: nasdaq:SCMP
- Website: sucampo.com
- Phone: 3019613440
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/sucampo-pharmaceuticals-187753 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.